---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-061980"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T23:09:31.021868+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acura gets $200k more loans from AD Pharma; warns cash may run out by mid-July 2025

## Summary
- Principal balance on AD Pharma secured note now $8,194,279; accrued interest ~$721k.
- Two new $100k loans received June 3 and June 20, 2025; interest at 5.25% (7.5% default).
- AD Pharma, which owns 65% of Acura's common stock, is the lender; controlled by Mr. Schutte.
- Without additional financing by mid-July 2025, Acura may furlough/lay off employees or seek bankruptcy protection.
- Company states no assurance additional financing will be obtained; proceeds used for day-to-day operations.

## SEC filing metadata
- accession: 0001104659-25-061980
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/0001104659-25-061980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/tm2518762d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-061980
- JSON: https://secwatch.observer/filing/0001104659-25-061980.json
- Plain text: https://secwatch.observer/filing/0001104659-25-061980.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: loans of $100,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On each of June 3, 2025 and June 20, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,194,279 with accrued interest of approximately $721,000 as of June 20 2025, and bears interest at 5.25% ("Note").
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925061980/0001104659-25-061980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.